AVR

https://www.sec.gov/ix?doc=/Archives/edgar/data/0002011514/000114036126022633/ny20074564x2_8k.htm

Barclays analyst Matt Miksic maintains Anteris Technologies Glb (NASDAQ:AVR) with a Overweight and raises the price target from $17 to $18.

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has strengthened its board with the appointments of experienced healthcare and finance executive Susan Knight and company veteran Stephen Denaro as directors. Knight joins as a Class I director, serving through to the company’s 2028 annual...

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported strong operational progress for the March 2026 quarter as the company advanced recruitment for its global PARADIGM pivotal trial and strengthened its balance sheet with US$320 million in capital raises. The structural heart...

Anteris Technologies Glb (NASDAQ:AVR) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.27) by 3.7 percent. This is a 54.1 percent increase over losses of $(0.61) per share

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has enrolled and successfully treated the first US patients in the global pivotal trial of its DurAVR® Transcatheter Heart Valve (THV) for severe calcific aortic stenosis. The procedures were carried out by Dr Azeem Latib at Montefiore...

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured US Medicare reimbursement eligibility for eligible procedures in its global pivotal PARADIGM Trial, a prospective, randomised controlled study designed to evaluate the safety and effectiveness of Anteris’ DurAVR® Transcatheter Heart...

Anteris Technologies CEO Wayne Paterson joined Steve Darling from Proactive to announce that the company has reached a major milestone by enrolling and treating the first patients in the United States for its DurAVR Transcatheter Heart Valve global pivotal trial. These landmark procedures were conducted at the Montefiore Medical Center in New York and were specifically performed for patients diagnosed with severe calcific aortic stenosis. Paterson noted during the announcement that conducting these initial U.S. cases within the global PARADIGM Trial represents a significant achievement for the investigators involved and offers valuable early procedural experience with the DurAVR THV System. The PARADIGM Trial is uniquely designed to address clinically meaningful questions that extend beyond standard safety metrics and basic hemodynamics. One of its core research objectives is to evaluate the specific impact of valve flow patterns on left ventricular recovery. According to the company, initiating this enrollment phase is a critical step in generating the high-quality evidence required to shape future standards of patient care. As a prospective randomized controlled trial, the study is set to evaluate the safety and clinical effectiveness of the DurAVR THV in direct comparison to various commercially available transcatheter aortic valve replacements currently on the market. The trial is expected to enroll approximately 1,000 patients into its 'All Comers Randomized Cohort'. Through a 1:1 randomization protocol, participants will be assigned to receive either the DurAVR THV or a standard TAVR using currently approved, commercially available heart valves. Ultimately, the trial investigators will assess non-inferiority based on a primary composite endpoint that tracks all-cause mortality, all instances of stroke, and cardiovascular-related hospitalizations exactly one year after the procedure has been completed. #proactiveinvestors #anteristechnologiesglobalcorp #asx #avr #nasdaq #avr #DurAVR #TAVR #HeartValve #ClinicalTrials #Cardiology #AorticStenosis #MedicalDevice #HealthcareInnovation #PARADIGMTrial #Biotech #MedTech #PatientCare #FDA #Cardiovascular

The S&P/ASX Small Ordinaries [XSO] closed at 3,458.80, gaining 15.20 points or 0.44% in the latest session. Over the past five days, the index has added 4.50 points, or 0.13%, pointing to a modestly positive tone across the small-cap market. Several ASX-listed companies have delivered...

-SEC Filing

MINNEAPOLIS and BRISBANE, Australia, April 28, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced it has secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services (CMS) national coverage poli

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured US Medicare reimbursement eligibility for eligible procedures in its global pivotal PARADIGM Trial, a prospective, randomised controlled study designed to evaluate the safety and effectiveness of Anteris’ DurAVR® Transcatheter Heart...

Eligible procedures performed at participating U.S. study sites are covered under the Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32. The CMS framework operates under a Coverage with

Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in over 130 patients. See why AVR is a Buy.

Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still evolving — and not always as quickly as patients, and investors, might expect. Nowhere is that more evident than in transcatheter aortic valve replacement (TAVR), a...

Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still evolving — and not always as quickly as patients, and investors, might expect. Nowhere is that more evident than in transcatheter aortic valve replacement (TAVR), a...

Cantor Fitzgerald analyst Gabie Ingoglia reiterates Anteris Technologies Glb (NASDAQ:AVR) with a Overweight and maintains $15 price target.

PARIS, March 18, 2026--Truffle Capital, a leading European venture capital firm whose mission is to support the creation and growth of companies capable of becoming global leaders, unveils the Truffle MedTech 10 index. This is the first ranking of the top ten publicly traded companies by market capitalization in the pre-commercial and early commercial interventional MedTech sector.

Anteris Technologies Global (NASDAQ:AVR) CEO and founder Wayne Paterson discussed the company’s DurAVR transcatheter aortic valve replacement (TAVR) program, recent clinical visibility, and the company’s approach to market development during a conversation that touched on product design, tissue scie